GRAIL, Inc. Common Stock (GRAL)
GRAIL, Inc. is a healthcare company focused on developing early detection tests for cancer and other life-threatening diseases using advanced genomic sequencing and data science. Founded with the goal of transforming cancer detection through blood tests, GRAIL leverages large-scale genomic research and machine learning to identify molecular markers associated with various cancers, aiming to enable earlier diagnosis and improve patient outcomes.
Company News
The global Minimal Residual Disease (MRD) Testing Market is projected to reach $4.50 billion by 2030, with a 10.1% CAGR, driven by increasing cancer diagnostic needs and personalized medicine approaches.
Quest Diagnostics reported strong Q1 2025 results, with revenue and earnings beating estimates. The company reaffirmed its full-year guidance and announced strategic acquisitions and partnerships, fueling confidence in its outlook.